For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

The toxic haze that blanketed large parts of India in November didn't just cloud the skies—it pushed sales of asthma and COPD medicines to their highest levels in three years.

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...

The Food and Drug Administration on Friday rejected Sunovion Pharmaceuticals’ treatment for chronic obstructive pulmonary disease. The late-stage drug is intended to serve as a long-term treatment for ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

The anti-asthma and COPD segment grew 10 percent year-on-year in November, outpacing historical winter trends and marking its ...